论文部分内容阅读
目的:研究乳腺癌血清CEA与癌灶转移的关系,并比较其在不同器官转移中的阳性率差异。方法:采用美国Beckman Coulter ACCESS全自动微粒子化学发光免疫分析仪检测1729个乳腺癌转移患者和9262个乳腺癌未转移患者的血清CEA水平。结果:乳腺癌转移患者血清CEA大于5.0为820例,阳性率为:820/1729=47.43%;乳腺癌未转移患者血清CEA大于5.0为837例,其阳性率为:837/9247=9.05%;单纯合并脑、肝、骨、肺、淋巴结转移的患者CEA阳性率分别为56%、48.11%、45.45%、34.26%、18.45%;结论:乳腺癌转移患者血清CEA阳性率高于未转移患者,乳腺癌分别发生脑、肝、骨、肺转移的CEA阳性率间无差别,但都高于乳腺癌淋巴结转移的患者,因此CEA确实可作为乳腺癌病情判断及预后的监测指标。
Objective: To study the relationship between CEA and metastasis of breast cancer and to compare the positive rate of CEA in different organs metastasis. Methods: Serum CEA level in 1729 breast cancer metastasis patients and 9262 breast cancer non-metastasis patients was detected by Beckman Coulter ACCESS automatic particle chemiluminescence immunoassay analyzer. Results: Serum CEA was more than 5.0 in 820 patients with breast cancer metastasis. The positive rate was 820/1729 = 47.43%. The serum CEA was more than 5.0 in 837 breast cancer patients without metastasis. The positive rate was 837/9247 = 9.05%. The positive rates of CEA in patients with simple brain, liver, bone, lung and lymph node metastasis were 56%, 48.11%, 45.45%, 34.26% and 18.45% respectively. Conclusion: The positive rate of CEA in patients with metastasis of breast cancer is higher than that in patients without metastasis, The incidence of CEA positive rates of brain, liver, bone and lung metastasis in breast cancer patients were all the same but higher than that in breast cancer patients with lymph node metastases. Therefore, CEA can indeed serve as a monitoring indicator for breast cancer prognosis and prognosis.